Does DNA ploidy and synthesis phase dynamic accentuate the predictive power of oestrogen and progesterone receptors in breast cancer progression and prognosis? by Sherbet, Gajanan V & Dlay, Satnam
 Deep Insight Section 
Review 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(9) 407 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
OPEN ACCESS JOURNAL AT INIST-CNRS 
Does DNA ploidy and synthesis phase dynamic 
accentuate the predictive power of oestrogen 
and progesterone receptors in breast cancer 
progression and prognosis? 
Gajanan V Sherbet, Satnam Dlay 
School of Engineering, University of Newcastle upon Tyne, UK; gajanan.sherbet@ncl.ac.uk; 
satnam.dlay@newcastle.ac.uk (GVS, SSD); Institute for Molecular Medicine, Huntington Beach CA, USA; 
gsherbet@immed.org (GVS) 
Published in Atlas Database: February 2018 
Online updated version : http://AtlasGeneticsOncology.org/Deep/DNAploidyERandPRinBreastCancerID20148.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/68946/11-2017-DNAploidyERandPRinBreastCancerID20148.pdf 
DOI: 10.4267/2042/68946
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2018 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Oestrogen and progesterone receptors (ER and PR) 
are closely associated with breast cancer 
progression. In this review we identify and discuss 
cellular markers that can accentuate or complement 
the deployment of ER and PR for predicting 
prognosis. The focus is on aneuploidy and DNA 
ploidy which appear to be significant independent 
predictors of overall survival in many forms of 
cancer. Their importance in cancer development and 
progression flows from their origin in the inherent 
genetic instability. Genetic instability of 
chromosomes is seen as aneuploidy, chromosomal 
deletions, translocations and sister-chromatid 
recombination, and at the DNA level as altered DNA 
repair, gene amplification and deletion and point 
mutations.  Microsatellite loci of repetitive 
nucleotide sequences are inherently unstable. 
Microsatellite instability is characterised by the loss 
of DNA mismatch repair activity leading to a 
hypermutable phenotype. Chromosome 
abnormalities result from the deregulation of cell 
cycle and immune checkpoint regulators. Failure of 
the DNA mismatch repair pathway could be one of 
the reasons for their incidence, although the 
available evidence is not unequivocal. Some 
tumours such as the colorectal carcinomas do not 
show an indisputable relationship between 
aneuploidy and microsatellite instability or 
mismatch repair deficiency. 
Epithelial mesenchymal transition (EMT) plays a 
crucial role in cancer biology. EMT is associated 
with the emergence and maintenance of cancer stem 
cells (CSC). Polyploidy and aneuploidy appear as a 
staging post to the formation of CSCs together with 
parallel activation of EMT. Chromosomal alterations 
may occur concomitantly with EMT as well as with 
the reverse process of mesenchymal epithelial 
transformation.  
Genetic profiling has revealed significant 
information concerning the abnormal growth 
kinetics of cancer cells. The DNA ploidy pattern is 
reflected in the polyploid and aneuploid states, 
aberrant gene amplification and expression and 
enlarged S-phase fraction. Aneuploidy may be a 
consequence of cells entering the S-phase of the cell 
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cycle prematurely.  DNA ploidy is also associated 
with aberrant expression of growth factor and 
hormone receptors. The DNA indices and the 
synthesis phase fraction (SPF) have been studied 
extensively in relation to tumour progression. The 
question we pose here is whether they enhance or 
counteract the function of ER/PR. Could they serve 
as complementary factors to predict prognosis of 
breast cancer. The expression of these cellular 
markers is quantified here by image cytometry 
(ICM) and the accrued data have been analysed by 
using binomial regression algorithm and the fuzzy 
K-Nearest Neighbour (FK-NN) classifier to see 
whether these cellular markers aid the prediction of 
nodal status and survival of breast cancer patients. 
The FK-NN analyses have revealed high prediction 
rates for both nodal involvement and 5-year survival. 
The FK-NN appears much superior in performance 
than techniques of logistic regression and multilayer 
feed-forward backpropagation (MLFFBPNN) the 
artificial neural network tool. A wide spectrum of 
evidence is presented here which supports the view 
that DNA ploidy and SPF acting as complementary 
factors accentuate the predictive power of ER/PR of 
breast cancer progression and provides credibility 
that they could deliver a more reliable prognostic 
model to assist in patient management. 
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Introduction 
Oestrogen and progesterone receptors (also named 
ERα and ERβ) and ) are closely associated with 
progression. The expression status of ER and PR is 
significant in determining response to endocrine 
therapy. Patients expressing both receptors have the 
best prognosis and are more likely to respond to 
hormone treatment than patients with ER+/PR- 
tumours. There is a view that PR+ patients might 
respond better to hormonal therapy. Since ER can 
induce the expression of PR, the reduced response to 
hormones could be a result of lack of normal ER 
function. Several growth factors and their receptors, 
e.g. (epidermal growth factor)/ (EGF receptor), 
activate non-receptor Src kinases to regulate many 
signalling pathways, including the Erk (extracellular 
signal-regulated kinases) cascade. In breast cancer 
cells, both oestrogens and progesterone can activate 
the Src/Erk pathway. This involves the interaction 
and crosstalk between their receptors (Migliaccio et 
al. 1998). Ballaré et al. (2003) have attributed this to 
the two domains of PR which interact with ER. On 
the other hand, progesterone can negatively regulate 
other oestrogen regulated signalling pathways 
leading to inhibition of proliferation (Chen et al. 
2005). Poor prognosis linked with the loss of 
progesterone/PR function could be a consequence of 
lack of suppression of ESR1 (ERα) (Thomas and 
Gustafsson, 2015). Furthermore, ERα and ER related 
receptors have been regarded as downstream targets 
of (human epidermal growth factor receptor 2, 
HER2) signalling (Chang et al. 2011). Even with the 
play of potential crosstalk between EGFR and HER2 
signalling, HER2 overexpression can negate anti-
oestrogen therapy. It was shown in an experimental 
setup some while ago that tumours formed in 
athymic nude mice by the implantation of ER+ 
MCF7 breast cancer cells transfected with HER2 did 
not respond to tamoxifen treatment (Benz e al. 
1992). Consistent with this, breast cancers 
overexpressing HER2 are often not responsive to 
anti-oestrogen therapy. At present we have no means 
to determine which patients might benefit from 
combining anti-oestrogen therapy with blockage of 
HER2 signalling (Rastelli and Crispino, 2008). 
Notably, luminal A subtype of breast cancers have 
shown high PR positivity and are HER2 negative 
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(Prat et al. 2013). Post-menopausal patients with 
advanced breast cancer appear to benefit 
significantly from combination of anti-hormone 
receptor and anti-HER2 therapy (Prat and Baselga, 
2008). Indeed, several signalling systems that can 
target ER and PR via HER2 can be identified. The 
crosstalk that takes place between ER and HER2 is 
obvious from the fact that oestrogen can activate 
HER2 signalling by inducing its phosphorylation 
and suppression of HER2 counteracts the effects of 
oestrogen on cell cycle distribution of an 
approximately 3-fold increase of S-phase cells. This 
increase was negated by HER2 suppression (Mullen 
et al. 2007). How the PR isoforms, PR-A, PR-B and 
PR-C, function in this context is yet unclear. PR-A 
is a ligand dependent repressor of PR-B. The PR-A 
and PR-B isoforms regulate different sets of target 
genes. The PR-B isoform is associated with increase 
in cell migration but not on cell proliferation or 
survival. PR-B activates many progesterone 
response genes by activatng Src/MAPK signalling 
pathways, which can promote or inhibit cell 
proliferation (see Sherbet, 2017b). As stated in 
another location, ER binds directly to the ERE half 
site/Sp1 binding site in the PR-A promoter (Petz and 
Nardulli. 2000). Thus much advance has been made 
on some fronts. But a basic precept has not been 
explored whether one can identify cellular markers 
that can accentuate or complement the deployment 
of ER and PR for predicting prognosis.  
 
Genetic instability and cytogenetic aberrations 
Genetic instability parallels the generation of cellular 
diversity, including the generation of variant sub-
populations with metastasising ability, within the 
tumour. Genetic instability occurs both at the DNA 
and the chromosomal levels. At the DNA level 
altered DNA repair properties, gene amplification 
and deletion and point mutations are indicators of 
genetic instability. Aneuploidy viz. the presence of 
abnormal number of chromosome, euploidy, 
chromosomal deletions, translocations, and sister-
chromatid recombination are chromosomal 
manifestations of genomic instability (see Sherbet 
and Lakshmi, 1997). Some of the early work on the 
relevance of DNA ploidy to cancer prognosis has 
been discussed in detail before (Sherbet, 2006). 
DNA ploidy has remained as a significant 
independent predictor of overall survival in many 
forms of cancer. The aneuploid state has correlated 
with the expression of established prognostic 
markers, such as the prostate specific antigen in 
prostate cancer. Correlations have also emerged 
between DNA ploidy and the expression of factors 
such as the matrix metalloproteinases and 
intercellular adhesive proteins which are conducive 
to the promotion of cancer invasion. Possibly the 
unfavourable prognosis seemingly associated with 
aneuploidy is linked with potential for invasion. 
Aneuploidy is also seen as being able to predict 
immune evasion by tumours since fewer immune 
cell infiltrations seem to be associated with 
aneuploidy (Davoli et al. 2017). But it is intriguing 
that they find that activating mutations of oncogenic 
pathways negatively correlated with the aneuploidy 
state, which basically runs counter to the view the 
genetic instability is the driving force of 
carcinogenesis. But then by definition mutability 
does reflect genetic instability.  
 
Microsatellite instability 
Genetic instability can occur at the nucleotide and or 
microsatellite level. Microsatellite loci are inherently 
unstable repetitive nucleotide sequences of varying 
lengths which occur in the human genome within 
genes and also between genes. The instability is seen 
in alterations in the repetitive units within the 
microsatellites altering the length of the loci. 
Microsatellite instability is characterised by the loss 
of DNA mismatch repair activity leading to a 
hypermutable phenotype. The instability can also 
affect non-repetitive sequences of the genome. 
Microsatellite repeats may occur outside the coding 
regions of genes; nonetheless, they can destabilise 
genetic function.  
 
The importance of microsatellite instability in 
tumorigenesis was recognised many years ago 
(Prolla, 1998). It is known that microsatellite 
instability can affect cell proliferation related genes 
and possibly also genes involved in invasion and 
metastasis. This is significant given that it has been 
encountered in parallel with cancer progression. 
Indeed, microsatellite instability has been regarded 
as a significant prognostic factor and it is a virtually 
invariable feature of tumours such as colorectal and 
endometrial cancers linked with the Lynch syndrome 
of hereditary predisposition to tumorigenesis.  
 
Microsatellite instability is often due to mutation of 
DNA mismatch repair genes such as , , , and and the 
gene coding for epithelial cell adhesion molecule 
(Modrich and Lahue, 1996; Chao and Lipkin, 2006; 
Li, 2008). Inactivating mutations of mismatch repair 
genes and modulation of gene expression by 
epigenetic silencing leads to the loss of mismatch 
repair and to microsatellite instability. EPCAM with 
the last 3' exons are deleted results in transcription 
read-through and silences the downstream MSH2 by 
promoter methylation. These events are 
aetiologically linked with (Ligtenberg et al. 2009; 
Kovacs et al. 2009). The abnormal repair proteins 
can be assessed to quantify DNA instability. In other 
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words, it is consanguineous with nucleotide 
instability.  
 
Given the link between microsatellite instability and 
defective mismatch repair, genetic instability would 
be expected to and does markedly influence drug 
resistance. The emergence of drug resistance under 
conditions of compromised DNA mismatch repair 
was recognised many years ago (Fink et al. 1998). A 
consequence of the loss of mismatch repair faculty is 
that the cell cannot detect the damage and access the 
apoptotic pathway. In this context, one has to 
accommodate the possibility that drug metabolism 
and the efflux of the drug may also be credible 
factors. Besides, as noted in the following section, 
the mismatch repair proteins are also involved in 
activating the cell cycle checkpoints.  
 
Cell cycle and immune checkpoint regulators and the 
effects of failure of surveillance 
Abnormalities in the regulation of the cell division 
cycle by aberrant expression and activity of 
regulators of and interference in checkpoint function 
are known to result in aneuploidy. Besides cell cycle 
checkpoint regulation immune checkpoint proteins 
also regulate the cell cycle. An important outcome of 
aneuploidy is inappropriate expression of genes 
associated with tumour growth, invasion and 
metastasis. The modulation of gene expression and 
the signalling systems that regulate tumour growth 
has frequently paralleled the incidence aneuploidy.  
 
The cell cycle traverse is regulated at phase 
transition points by checkpoint proteins. The G1 
(G1/S) and G2 (G2/M) are DNA damage checkpoints 
with different surveillance functions. The G1 
monitors DNA damage and blocks progression at 
G1/S transition. The interference with DNA 
synthesis or the repair of DNA lesions arrests the cell 
cycle at G2/M transition so that damaged cells are not 
replicated. There are intra-S-phase checkpoint 
pathways that regulate DNA replication and delay or 
halt S-phase progression. Several cell cycle and 
immune checkpoint regulator proteins have been 
identified to-date. Notable among cell cycle 
regulators are and the proteins which were 
recognised as cell cycle checkpoint proteins many 
years ago (Kuerbitz et al. 1992; Sherr, 1994). They 
regulate the G1/S checkpoint. This checkpoint is 
invariably deregulated in tumours. Both p53 and Rb1 
are viewed as tetraploid checkpoint proteins since 
they can suppress tetraploid cells from replicating 
and suppress tumorigenesis (Margolis et al. 2003; 
Fujiwara et al. 2005).  
 
Interference with the cytoskeletal machinery also 
arrests the cells at G2/M transition preventing their 
entry into mitosis. The spindle or mitotic checkpoint 
monitors the microtubule integrity and prevents 
progression if that has been compromised. 
Deregulation of checkpoint control would lead to 
chromosomal aberrations and aneuploidy and 
hyperploidy. In mitosis the sister chromatids attach 
to the mitotic spindle, are aligned and separated 
during anaphase. Failure of mitotic checkpoint 
surveillance, essentially of correct attachment to the 
spindle, leads to abnormal chromosomal segregation 
and to aneuploidy. Total failure of mitotic 
checkpoint function can lead to hyperploid states on 
account of chromosome non-disjunction. Several 
highly conserved spindle checkpoint proteins have 
been identified. The spindle checkpoint proteins, 
(Mitotic Arrest Deficient 1-3), the , , (Budding 
Uninhibited by Benzamidazol) 1-3, and Mps1 
(Monopolar spindle 1) (see Shah and Cleveland, 
2000) have been studied extensively. They operate 
different pathways (see Amon, 1999; Burke, 2000; 
May and Hardwick, 2006).  
The mitotic spindle checkpoint proteins are also 
involved with the maintenance of genomic stability. 
Their deregulation results in chromosomal 
instability. Mutations have been seen in the genes 
coding for these checkpoint proteins in many 
cancers. Colorectal cancer cell lines displaying 
chromosomal instability also had defects in spindle 
checkpoint. In cell lines displaying chromosomal 
instability, the Bub1 gene, encoding an important 
component of the spindle assembly checkpoint 
protein, was inactivated by mutation (Cahill et al. 
1998). Reduction of expression of eukaryotic protein 
BUB1B (BubR1) by mutations and 
haploinsufficiency can result in aneuploidy. Its 
overexpression has a protective effect (Baker et al. 
2008, 2009, 2013).  
 
Cytogenetic aberrations and their influence on 
tumour biology  
In the current environment, the correlation of 
cytogenetic abnormalities of DNA ploidy with 
aberrations of SPF has been the subject of much 
debate. There is ample justification for exploring the 
interrelationship between DNA ploidy and SPF. As 
discussed before abnormalities of DNA ploidy are 
closely correlated with the aggressive behaviour of 
tumours. Both tend to reflect the rapidity of tumour 
growth, possibly actuated by different mechanisms. 
But tumours and tumour derived cell populations are 
likely to display differential sensitivity to drugs. For 
example, drugs intercalating into the DNA and 
microtubule stabilisers would target cells with 
different chromosomal abnormalities. The growth of 
polyploid tumours and cell lines might be an 
outcome of the number of gene copies of the relevant 
determinants whilst SPF would portray the cells in 
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the DNA synthesis phase and hence the size of 
actively proliferating or cycling subpopulation.  
 
It has been suggested that aneuploidy may be a 
consequence of cells entering the S-phase 
prematurely. Furthermore, DNA ploidy is associated 
with expression of growth factor and hormone 
receptors, a topic at the centre of discussion in this 
review. Major shifts in DNA index may have some 
bearing on the progression of cancer since many 
genomic changes are encountered as chromosomal 
euploidy and aneuploidy and as chromosomal 
aberrations, translocations and sister chromatid 
recombinations. These could have arisen by 
cumulative genetic changes resulting from loss of 
cell cycle control. An important proviso to note is the 
heterogeneity of tumours of the expression of 
biochemical markers. The heterogeneity also 
encompasses DNA ploidy (Sherbet and Lakshmi, 
1997).  
 
Some features such as DNA index and the size of the 
SPF have been studied extensively with variable 
results. Whether these might potentiate or counteract 
the function of ER/PR has not been investigated. 
Here we describe the potential of these features in 
conjunction with the expression of ER and PR and 
evaluate whether they serve as complementary 
factors to predict prognosis of breast cancer.  
 
DNA ploidy and epithelial mesenchymal 
transition 
Several genetic determinants and their downstream 
signalling cascades lead to the activation of the 
developmental mechanism of epithelial 
mesenchymal transition (EMT). EMT plays a crucial 
role in cancer biology. A molecular concept of 
cancer progression has evolved over the years, which 
has provided a solid basis for the cancer stem cell 
(CSC) hypothesis. The CSC hypothesis postulates a 
temporal acquisition of stem cell characteristics 
upon activation of the EMT pathway, since EMT is 
invariably accompanied by the generation and the 
perpetuation of CSCs with corresponding tumour 
growth, invasion, angiogenesis and metastasis. The 
emergence of the CSCs has also been linked with 
drug resistance. Several pathways activated by 
growth factors and other biological response 
modifiers steer the cell phenotype towards EMT. 
Notable among them besides the growth factors are 
Wnt, Notch and the Hippo. Furthermore, Notch 
ligands can integrate their signalling with Wnt and 
TGF-β pathways. The appearance of CSCs is often 
accompanied by the persistent activation of these 
signalling systems (Sherbet, 2013, 2017a).  
 
The polyploid state has been implicated as a staging 
post to the formation of CSCs accompanied by the 
expression of EMT related transcription factors. It 
has been postulated that chromosomal alterations 
can be seen with EMT activation. In ovarian tumours 
the presence of groups of a subpopulation of giant 
polyploid cells has been described. These gave rise 
to CSCs with some groups also displaying EMT 
characterisitics (Zhang et al. 2013, 2014). Whether 
these cells had gone on to produce metastasis is 
uncertain since no in vivo assays had been 
performed. Gao et al (2016) have argued that EMT 
activation can occur spontaneously and the 
generated variants undergo chromosomal changes 
causing the deletion or acquisition of genes whose 
expression might be connected to cancer 
progression.  
 
The ability of stem cells to self-renew and 
differentiate into a wide spectrum of cell types 
implies the gain of phenotypic diversity and 
heterogeneity of function. CSCs are also 
heterogeneous. Further, the innate ability to diversify 
phenotypically is at the root of intratumoral 
heterogeneity. Both these features may be spawned 
by differential signalling to external factors resulting 
in differential display of CSC as well as EMT 
markers together with drug resistance and significant 
connotation for therapy. The common stem cell 
pathways such as growth factor/receptor, Wnt, and 
Notch signalling and the downstream effectors such 
as MAPK, Akt signalling could be differentially 
activated in most stem cells, including CSCs. This 
would lead to the diversification of CSCs and their 
self-renewal bringing about intratumoral 
heterogeneity in their wake. The reverse process of 
MET (mesenchymal epithelial transformation) 
would by similar rationale create intratumoral 
heterogeneity.  
 
One can translate this concept more precisely with 
reference to tumour progression to the metastatic 
state. Although CSC generation and EMT might go 
hand in hand by virtue of the identity of the 
signalling systems, diverse pathways might be 
activated within the EMT signalling that might lead 
to the generation of functionally different CSCs. The 
expression of CSC features and EMT activation are 
regulated by certain transcription factors, whose 
expression is itself subject to subtle regulation. Their 
stabilisation by protecting them from ubiquitination 
is essential for the promotion of metastasis (Lin et al. 
2017).  
 
The aberrant expression of mitotic checkpoint 
proteins has been linked with the emergence of the 
EMT phenotype. The ribonucleic acid export 1 ( ), 
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cancer 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(9) 412 
 
which is involved in mRNA export, is known to 
serve as a mitotic checkpoint regulator. 
Haploinsufficient and/or hypomorphic alleles of 
RAE1 lead to chromosome mis-segregation and 
aneuploidy (Baker et al. 2006). However 
contrastingly, overexpression of RAE1 has been 
correlated with increased in vitro migration of cell 
lines achieved by the initiation of EMT as 
characterised by the enhanced expression of 
mesenchymal and downregulated expression of 
epithelial markers. Furthermore, RAE1 
overexpression negatively correlated with DFS 
(disease free survival) and metastasis-free survival 
(Oh et al. 2017). These authors allude to the effects 
of the overexpression of RAE on chromosomal 
instability and aneuploidy. However, they did not 
look at chromosomal aberrations or instability under 
conditions where RAE1 was overexpressed. This 
would have established a direct relationship between 
the expression of the checkpoint regulator and the 
initiation of EMT. So some reservations may need to 
be expressed in relation to how the relationship 
between RAE1, aneuploidy and EMT might pan out 
in due course.  
 
The protein is a regulator of cell differentiation, 
proliferation as well as apoptosis. The 
overexpression of myc is frequently associated with 
polyploidy. Vazquez-Martin et al. (2016) found that 
a whole scenario of myc function correlated with the 
overexpression of myc-interacting proteins and 
paralleled EMT activation. Not only does myc 
interact with proteins overexpressed in the polyploid 
state, but also with two immune checkpoint proteins, 
and (PD-L1) (Casey et al. 2016). CD47 regulates 
many signalling systems related to CSC self-
renewal, and tumour initiation, growth and invasion. 
Tumours adopt certain immune checkpoint 
pathways especially against tumour-specific T cells. 
This leads to immune resistance. The CD28 family 
proteins PD1/ / and their ligands are prominent in 
immunotherapy (Sherbet, 2017a). Tumours 
displaying mismatch repair deficiency and high 
microsatellite instability are highly sensitive to 
immune checkpoint inhibitors (Lee et al. 2016). 
Many tumour types, among them triple negative 
(ER-/PR-/HER2-) breast cancers and , overexpress 
PD-1 and its ligands (Gatalica et al. 2014). Gadducci 
and Guerrieri (2017) reported recently that 
endometrial cancers with high microsatellite 
instability overexpress PD-1 and PD-L1 and so are 
prone to suppression by blockade of the PD-1)/PD-
L1 pathway. Therefore, one might be justified in 
envisioning a rational linkup between microsatellite 
instability and the incidence and prognostic 
importance of DNA ploidy.  
 
Oestrogen and progesterone receptors and breast 
cancer progression 
Breast cancer is one of the most common cancers 
that affects one in ten women, and is a most frequent 
cause of cancer death in women. Breast cancer 
treatment and patient management is based on the 
state of progression of the disease. This is indicated 
by the presence of the tumour in axillary lymph 
nodes and the number affected nodes. In recent years 
much effort has been made to identify molecular and 
cell markers that might have the potential to 
accurately assess the state of progression and predict 
prognosis. Oestrogen and progesterone are known to 
affect the growth of a variety of tissues, including 
breast tissue. Oestrogens and anti-oestrogens bind to 
oestrogen receptors ERα and ERβ. The presence of 
ER indicates the state of tumour differentiation. The 
absence of ER in breast cancer as an indicator of 
poor prognosis, since ER- tumours are resistant to 
anti-oestrogen therapy, continue rapid growth and 
result in poor outcome for patients. However, this is 
not an outcome attributable exclusively to the 
absence of ER.  
 
ER and PR are closely associated with breast cancer 
progression. ER and PR expression status is 
significant in determining response to endocrine 
therapy. Functional PR might be required for growth 
signalling by ER. Patients expressing both receptors 
have the best prognosis and are more likely to 
respond to hormone treatment than patients with 
ER+/PR- tumours (Osborne, 1998). Since ER can 
induce the expression of PR, the reduced response to 
hormones could indicate a non-functional state of 
ER. In breast cancer cells, both oestrogens and 
progesterone and their receptors can collaboratively 
activate the Src/Erk pathway and promote cell 
proliferation. On the other hand, progesterone can 
negatively regulate other oestrogen-regulated 
signalling pathways leading to the inhibition of 
proliferation (Chen et al. 2005).  
 
The importance of ER/PR is further highlighted by 
the possibility that ER/PR signalling can interact 
with the p53 pathway. Also ER has been implicated 
in the regulation of this p14ARF-mdm2-p53 
pathway (Cho et al. 2006). The transcription factor 
Twist is known to suppress the p14ARF ( ). This in 
turn leads to the suppression mediated regulation of 
p53 and to premature G1/S transition and cell 
proliferation. , a bHLH transcription factor, 
downregulates the expression of (E-cadherin) and 
activates EMT. This reasoning is on lines similar to 
the repression of p14ARF by the T-box transcription 
factor to initiate EMT. One would recall that Tbx2 is 
overexpressed in cancer and in embryonic systems 
(Abrahams et al. 2010) and is a potent activator of 
EMT (Wang et al. 2012). Finally, transfection of ER 
Oestrogen and progesterone receptors in breast 
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into MCF7 cells had led to the expression of markers 
associated with EMT activation (Bouris et al. 2015). 
Thus the involvement of ER in the 
p14ARF/mdm2/p53 pathway to EMT activation 
may be deemed to be complete.  
 
Further evidence one can adduce is that (trefoil 
factor 1; pS2), a downstream target of ERα, is 
downregulated in some forms of cancer. TFF1 
impedes G1/S transition, inhibits cell proliferation 
and induces apoptosis by activating p53 (Calnan et 
al. 1999; Bossenmeyer-Pourie et al. 2002; Haupt et 
al. 2003). ERα binds to p53 and downregulates p53 
expression and suppresses the expression of p53 
responsive genes that inhibit cell proliferation. This 
can also occur by the upregulation of TFF1 (Konduri 
et al. 2010). Furthermore, ER has been linked with 
signalling by EGFR and HER2. Of considerable 
interest from the point of view of progression of 
breast cancer to the metastatic state is that molecular 
markers of cancer metastasis such as the metastasis 
promoter and the suppressor nm23 might 
conceivably contribute to the metastatic spread in 
association with functional ER/PR (Grey et al. 
2003).  
 
The expression status PR, along with that of ER, is 
routinely measured in breast cancer specimens. PR 
is an oestrogen responsive gene and so PR positivity 
indicates not only ER being present but also 
functional (Horwitz and McGuire, 1975). However, 
a small proportion of tumours are ER-/PR+ and still 
respond more favourably to hormonal therapies than 
ER-/PR- tumours (Osborne, 1998; Osborne et al. 
2005). Also, ER+/PR- may be less responsive to 
hormonal therapy than ER+/PR+ patients (Lapidus 
et al. 1998). This demonstrates the non-aligned 
importance of PR in breast cancer development and 
treatment, and that it is not just as an adjunct of ER 
function. We recently showed that a clear distinction 
can be made between PR and ER, with PR displaying 
greater correlation than ER with disease progression 
and prognosis (Caronongan III et al. 2016, Sherbet 
2017b). The cell proliferation/survival results 
depend upon the ER/PR signalling axis subject to the 
provision of which isoform of ER or PR is functional 
and the recognition that ER does influence PR 
function. ERα and ERβ are two ER isoforms. PR also 
may be expressed in three functionally different 
isoforms (Kariagina et al. 2008). The promoter of the 
PR-A isoform contains an ERE half site/Sp1 binding 
site and ER does bind directly to this site (Petz and 
Nardulli. 2000). ERα is pro-proliferation whilst ERβ 
is inhibitory of cell proliferation. Besides, ERα binds 
to and downregulates PRβ (Sherbet 2017b).  
 
The connotation of ER and PR on DNA ploidy, 
SPF and cell cycle distribution 
Some features such as DNA index and the size of the 
SPF have been studied extensively over the years for 
potential impact on breast cancer progression and 
prognosis, but no substantive outcome has been 
recorded. Notably not addressed with apparent 
intensity is whether these might potentiate or 
counteract the function of ER/PR. One would recall 
here that intratumoral heterogeneity is a common 
feature. Significant heterogeneity in the distribution 
of many markers including PR, ER, p53, and (Ki-67) 
has been encountered in breast cancer. The 
heterogeneity of ER and PR expression has been 
amply demonstrated using, immunohistochemical 
and radioactively labelled ligand binding assays. The 
two assays have also revealed a clear functional 
distinction between PR and ER in respect of clinical 
outcome (Table 1). This could be a reflection of the 
fact that LBA provides information about the totality 
of receptor expression irrespective of intratumoral 
distribution. In contrast, IHC based designation of 
receptor positivity provides the proportion and 
intensity of staining of tumour cells reflecting 
potential heterogeneity of distribution.  
  
Table 1.Intratumoral heterogeneity of ER and PR 
expression 
ParameterTested  IHC  LBA  
ER vs node  -  +  
PR vs node  +  -  
      
ER vs DFS  -  -  
PR vs DFS  +  +  
Note: This table emphasises the differential correlation of 
the receptors with nodal positivity and DFS (disease-free 
ssurvival). ER positively correlated with node positivity by 
LBA but PR by IHC. PR status correlated with DFS in both 
assays, but ER status did not by either assay. This could be 
suggestive of intratumoral heterogeneity of receptor 
expression. IHC: Immunohistochemistry; LBA: Ligand 
binding assay. (Modified from Caronongon III et al. 
(2017) 
 
Measurement of cellular markers 
The method most popularly employed in the study of 
cellular markers, such as DNA index, size of SPF, 
and cell cycle distribution (CCD), is flow cytometry. 
Much less in vogue is Image cytometric data (ICM). 
The ICM method can measure the cellular features 
of cell aspirates and in stained tissue sections. 
Nuclear pleomorphism, which possibly reflects the 
degree of deviation of cancer cells from normal 
morphological configuration, is an important 
criterion in tumour grading. However, it could suffer 
from subjectivity of assessment. This can be 
overcome by quantifying the degree of 
pleomorphism using ICM technology (Lakshmi and 
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Sherbet, 1990) and has been measured free of bias. 
The ICM data mostly relate DNA ploidy, size of SPF 
and CCD data presented as a ratio of number of cells 
in G0 G1 over the number of cells in G2M (G0 G1/ 
G2M). The presence of more than 10% of cells in the 
G2M peak of cell cycle is often considered to be an 
indicator of aneuploidy and therefore the G0 G1/ 
G2M ratio can be used an additional parameter. A 
normal cell population will present an SPF around 
4% and >10% suggests a high rate of proliferation 
(Lakshmi and Sherbet, 1990; Naguib et al. 1999). 
The ICM measures are limited unlike flow 
cytometry which has a wide spectrum of capabilities. 
These include immunotyping with fluorescence-
labelled antibodies, measuring the intensity of 
antigen expression, cell sorting and high speed 
analysis. The limitation of the technique is that one 
requires strictly unicellular suspensions and hence 
the adhesive faculty of cells comes into the 
reckoning. Also recognised is that flow cytometry 
does not provide any information on the spatial 
distribution in tissues of the cells of interest (Davey 
and Kell, 1996; Craig and Foon, 2008).  
 
The perception and perspective of applicability of 
cellular and molecular markers to prognosis 
The potential importance of DNA content and SPF 
in relation to cancer prognosis has lately received 
much concerted attention. A recent meta-analysis of 
breast cancer data has highlighted the association of 
DNA aneuploidy with higher tumour grade, tumour 
dissemination to the lymph nodes with ER positivity. 
ER, PR and DNA ploidy are generally endorsed as 
useful biomarkers for endometrial cancer. Both 
ploidy and SPF may reflect extension of endometrial 
carcinoma to the lymph nodes. Lymphovascular 
invasion and concomitant reduced recurrence-free 
survival was associated with the aneuploidy and SPF 
(Song et al. 2012). Lymphovascular invasion i.e. the 
presence of tumour emboli, located distal from but 
not close to the tumour, in the peritumoral region 
was related prognostically to metastasis-free 
survival (De Mascarel et al. 2009). However, the 
tumour emboli focused on by Song et al. (2012) 
seem to be in close proximity of the tumour. De 
Mascarel et al. (2009) had ruled out any prognostic 
value to emboli located close to the tumour. This is 
compatible with the commonly held view 
concerning metastatic dissemination. Numerous 
emboli and tumour cells may enter the 
lymphovascular system but infiltration into the 
system may not be fully reflected in overt metastatic 
foci. Song et al. (2012) had not looked at the steroid 
receptor status in their work. Nevertheless, Song et 
al. (2011) had reported earlier that lymphovascular 
invasion was associated with ER expression, but not 
PR, HER2 or p53. This was in node-positive breast 
cancer, but corresponding data relating to node-
negatives tumours was also described. So at present 
some uncertainty surrounds the status of ER/PR in 
relation to ploidy and SPF. But a recent report has 
stated that aneuploidy is seen also in ER/PR negative 
endometrial tumours, where aneuploidy 
independently predicted survival (Mauland et al. 
2017). One has to be mindful of considering the 
expression status of ER and PR and be circumspect 
about this since they would have opposing biological 
effects; so do the ER isoforms biologically oppose 
each other.  
 
Crosstalk between hormone and growth factor 
signalling and DNA ploidy  
We have arrived at a point when it is arguable 
whether genetic instability bears any relationship 
with the expression of ER and PR, cancer 
progression and with any perceived sensitivity of 
tumour cells to steroid hormones. In the preceding 
section we have briefly explored also whether 
ER/PR expression is related to the incidence of DNA 
ploidy and related features of SPF and CCD as 
manifestations of genetic instability. Thus we 
complete the circuitry of the inter-dependence of 
genetic instability, steroid receptors and sensitivity 
of tumours to endocrine therapy, but without 
invoking causality. Nonetheless, given this 
background it would seem eminently worthwhile to 
attempt to determine if the prognostic value of 
ER/PR status can be enhanced by combining the 
steroid expression status with cell proliferation 
features such as DNA ploidy, and SPF 
measurements and CCD.  
 
The basic thesis of a potential link between genetic 
instability manifested as DNA ploidy and sensitivity 
to endocrine therapy was postulated some time ago. 
ER positivity of the breast cancer cell line T47D 
corresponded with DNA ploidy (Reddel et al. 1988). 
However, one has to add a rider here that the 
sensitivity of the breast cancer cell lines to anti-
oestrogens is complicated by a number of factors. 
The cell line T47D is ER+/mutant p53+, MCF-7 is 
ER+/wild-type p53+ and MDA-MB-231 is ER-
/mutant p53+. Furthermore, MDA-MB-231 cells do 
indeed overexpress HER2 (see Sherbet, 2013). So 
the sensitivity or insensitivity of these cell lines to 
growth suppression might be determined by more 
than a single growth promoter.  
 
It was reported over a couple of decades ago that 
among the biomarkers which included p53, ER, PR, 
EGFR and HER2, DNA ploidy was found to be most 
highly predictive of recurrent endometrial cancers. 
HER2 was a significant factor, but surprisingly 
EGFR overexpression was not (Lukes et al. 1994). 
However, we do not know much about the inter-
relationship between them and whether the 
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expression of a specified marker influences the 
significance of the rest. The discordance noticed 
between the importance of HER2 and EGFR is 
difficult to interpret in terms of their consequence to 
prognosis. One should recall that EGFR ligands can 
also interact with HER2 and generate biological 
effects. More recently, some effort has been made to 
check if the level of DNA ploidy was associated with 
the expression of PR and HER2 (Dayal et al. 2013). 
Low DNA index was associated with PR positive 
state and wildtype P53, compatible with their 
proliferation suppresser effects. Compatible also is 
the finding that high DNA index correlated with 
HER2 positivity. However, it would have been 
useful to know the relationship between ploidy and 
ER and PR isoforms, which subserve opposing 
functions.  
 
Much archival work can be cited which has revealed 
a significant correlation between the expression of 
both EGFR and HER2 and the associated enhanced 
cell proliferation with aneuploidy breast cancers 
(Fernandez et al. 2002). The situation obtaining in 
ovarian cancer is totally at variance with this. 
Although EGFR expression was more frequently 
noted in overt cancer as opposed to borderline 
malignancies, the expression levels showed no 
correlation with DNA ploidy (Nagai et al. 2001). 
Recent research tends to be more positively inclined 
about this topic. Uesugi et al. (2017) stated that there 
was a significant linkup between the overexpression 
of HER2 as well as p53 and microsatellite instability. 
In an opposing view Birkness et al. (2018) found no 
correlation between chromosome polysomy, i.e. the 
presence of multiple copies of chromosome, with 
HER2 amplification. However, polysomy is an 
indicator of genetic instability. So Birkness et al. 
(2018) have advocated that microsatellite instability 
and chromosomal instability may be unrelated and 
not inter-dependent events. But in sharp contrast to 
this in colorectal cancer chromosome copy numbers 
have correlated with microsatellite instability 
(Jasmine et al. 2012). Therefore any distinction 
between chromosomal instability and microsatellite 
instability may yet be regarded as inauthentic. There 
is further substantiation of this below. In both EGFR 
and HER2 overexpression has strongly correlated 
with aneuploidy. Activation of Akt and 
EGFR/HER2 was related to DNA aneuloidy 
(Hisamatsu et al. 2016). Yaglom et al. (2014) 
demonstrated that HER2 was able to induce genetic 
instability by downregulating the pathways of repair 
of double strand DNA lesions. The ambiguity in the 
interrelationship between the overexpression of 
these growth factor receptors and chromosomal 
instability gains further credibility with the 
revelation in many recent studies that in a -deficient 
environment genetic instability can occur 
independently of DNA double strand repair (Gupta 
et al. 2009). This leads one to speculate that 
activation of the HER2/PI3K/Akt signalling axis 
could have led to genetic instability.  
 
Alu (short interspersed element) Sine repeats and 
Line (long interspersed elements) elements are a 
recognised source of genetic instability. They are 
retrotransposons which can produce major genetic 
changes with the potential to lead to tumorigenesis. 
There is a general perception that methylation of the 
transposable elements suppresses their mobility and 
is conducive to genetic stability. Hypomethylation is 
encountered in many disease states including cancer; 
it is associated with aberrant gene activation and is 
possibly one of the provisions by which genetic 
instability might drive the neoplastic process. The 
insertion of the mobile elements can affect the 
expression of the genes in the proximity of the site 
of insertion. Since the epigenetic changes are stably 
inherited, the methylation status of the transposable 
elements assumes much functional significance 
(Ikeda and Nisshimura, 2015). Genomic instability 
can lead to the generation of chromosomal 
abnormalities (Bae et al 2012; Saito et al. 2010). The 
postulate here is that hypomethylation of these 
elements leads o chromosomal instability and to 
genetic abnormalities such as loss of heterozygosity 
and chromosomal translocations and that this would 
have serious implication for disease prognosis. 
Although loss of heterozygosity has been shown to 
occur no linkup is seen between hypomethylation 
and the incidence of genetic abnormalities. It is of 
some interest to note in the present context that 
hypomethylation of both Alu and Line elements was 
associated with a breast cancer subpopulation 
overexpressing HER2 and p53. Also 
hypomethylation of a Line element was seen in ER- 
tumours (Park et al. 2014). These authors omitted to 
check PR status in this work. As stated in an earlier 
section PR-A does contain an ERE half site/Sp1 
binding site to which oestrogen can bind and so PR-
A can respond to oestrogen even in the absence of 
ER.  
 
Notwithstanding the dissensions concerning the 
relationship of growth factor and steroid receptors to 
genomic instability, aneuploidy is considered to be 
significantly predictive of breast cancer prognosis 
(Xu et al. 2016). Aneuploid tumours showed high 
SPF and this correlated with advanced stage disease 
(Pinto et al. 2013, Bianco et al. 2013). Dayal et al. 
(2013) reported that in the breast cancer series that 
they had analysed high SPF was associated with poor 
survival. Indeed SPF was identified some while ago 
as a significant factor for the prediction of nodal 
involvement and survival (Naguib et al. 1999; Seker 
et al. 2002).  
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In abnormal DNA ploidy and the loss of PTEN gene 
that suppresses the anti-apoptosis effect of Akt 
signalling and the deletion of 6q15 correlated 
significantly with tumour grade and stage and nodal 
involvement. These deletions reflect chromosomal 
instability. The deletion of 6q15 which harbours 
gene is a frequent event in prostate cancer. The loss 
of this gene corresponds with Gleason grade. The 
MAP3K7 (mitogen-activated protein kinase kinase 
kinase 7) gene suppresses cell proliferation and 
invasion (Wu et al. 2012). This kinase negatively 
regulates the cell survival factor NF-κB. Combining 
DNA ploidy and the deletion status, both arising 
from genetic instability, were markedly powerful 
predictors of poor prognosis (Lennartz et al. 2016). 
So too in colorectal tumours aneuploidy has been 
linked with advanced Duke stage and found to be 
predictive of prognosis (Laubert et al. 2015).  
Alexiou et al. (2013) investigated the intracranial 
tumours and Cell cycle analyses and SPF 
determinations differed markedly between low grade 
and high grade gliomas. Furthermore, they found 
most glioblastomas to be aneuploidy. However, 
Carloni et al. (2017) found that DNA ploidy was not 
related to SPF in . They found hyperdiploidy was 
encountered more frequently in primary carcinomas 
than in recurrent tumours. The primary tumours were 
larger in size than the recurrent ones. But one cannot 
place much weight on the tumour sizes as regards 
growth potential. Although SPF did not show any 
relationship to ploidy, higher SPF correlated with 
reduced patient survival in the hyperdiploid group. 
SPF has been viewed by many as an independent 
prognostic factor, but information is scarce 
regarding the influence of ER/PR or growth factor 
family receptors on its expression.  
 
The perspective of DNA ploidy, SPF and ER/PR in 
cancer progression and prognosis 
Some years ago, O'Reilly et al. (1990) reported that 
the median SPF was higher in aneuploidy tumours as 
compared with diploid tumours and that it correlated 
with high Bloom-Richardson histological grade, but 
they found no correlation between SPF and DNA 
ploidy, nodal status or steroid receptor expression. 
The Bloom-Richardson system is probably not as 
reproducible as one would like, but cell proliferation 
index is a better prognostic marker.  
 
Much valuable information about the relevance of 
cellular markers for the prediction of cancer 
prognosis has also been collated using data obtained 
by ICM technology. We had noted previously that 
both nodal involvement and 5-year disease-free 
survival could be predicted a high degree of accuracy 
when ER/PR status was combined with DNA ploidy, 
SPF and CCD represented by the G0 G1/ G2M ratios 
the cell cycle distribution. CCD is indeed a measure 
of DNA index. It would be reasonable to suggest that 
our analysis does show a conspicuous linkup 
between nodal involvement and ER/PR expression 
status together with DNA index as revealed by DNA 
ploidy and CCD.  
 
Cellular and molecular marker expression analysis 
by binomial regression algorithm  
Even with this background information there have 
been no significant efforts to examine the utility of 
these cellular features in the background of steroid 
receptor expression to evaluate whether they might 
serve as complementary factors to predict prognosis 
of breast cancer. Andronas et al. (2003) analysed the 
possible influences of ER and PR expression in 
breast cancer in conjunction with the cellular 
markers and the influence they brought to bear 
individually or in combination on the nodal 
dissemination and 5-year DFS of patients with breast 
cancer.  
 
The query addressed was whether DNA ploidy, SPF 
and CCD displayed significant correlation with the 
presence of metastatic tumour in the regional lymph 
nodes and patient survival and to project any 
potential enhancement of the prognostic value of the 
steroid receptors by combining with cellular markers 
in patient management. The analyses, carried out 
using Matlab technical computing environment 
(Maths Works Inc.), were based on an algorithm 
designed and implemented to perform polynomial 
regression analysis of the data. Andronas et al. 
(2003) concluded that ER and PR exerted 
differential effects on the cell features examined. 
Whilst PR influenced both DNA ploidy and SPF, ER 
had no influence on either. However, there was some 
interrelationship between these two features since 
DNA ploidy/SPF taken together were influenced by 
ER but not by PR (Tables 2).  
  
Table 2. Influence of ER/PR on DNA ploidy, SPF and cell 
cycle distribution by polynomial regression analysis 
Cellular marker   ER   PR 
DNA ploidy  -  + 
SPF  -  + 
DNA and SPF  +  - 
DNA and G0G1/G2M (CCD)  +  - 
G0G1/G2M (CCD  +   
Based on Andronas et al. (2003).  
  
Table 3. Prediction of nodal status and survival by 
polynomial regression analysis 
Steroid Receptor Status 
Prediction accuracy 
Nodal status     5-year DFS 
ER+/PR+ 10/16 (81%) 15/16 (94%) 
ER+/PR- 8/14 (55%) 12/14 (86%) 
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ER-/PR- 11/16 (69%) 13/16 (88%) 
Based on Andronas et al. (2003). DFS: Disease free 
survival 
 
It is obvious from the data generated by these 
analyses that the expression of both ER and PR 
provides high prediction accuracy for the both nodal 
status and 5-year DFS. In the ER+/PR- group the 
accuracy nodal prediction was markedly reduced 
indicating that ER might not be fully active due to 
the absence of PR. Even more interesting is that the 
prediction rates for nodal status as well as survival 
ER-/PR- group was more or less similar to that in the 
ER+/PR- group, but far lower that obtained with the 
ER+/PR+ group (Table 3). Given that ER influenced 
all the cellular markers but PR influenced only SPF, 
it would not be unreasonable to suggest from these 
prediction rates that the cellular markers could be 
regarded as partly independent prognostic factors.  
 
The multilayer perceptron (MLP) has been shown to 
be an effective vehicle for exploring the predictive 
potential of these biomarkers. The MLP-based 
analysis has provided accurate and reliable 
prediction for breast cancer given that an appropriate 
design and validation method was employed 
(Mojarad et al. 2010, 2011). Nevertheless, we have 
looked for supportive evidence by analysing the data 
set of Andronas et al. (2003) aided by more 
sophisticated analyses, viz. by using the Fuzzy K-
Nearest Neighbour (FK-NN) algorithm, of which the 
methodology is briefly described below.  
 
The Fuzzy K-Nearest Neighbour (FK-NN) 
algorithm 
The two techniques widely used to analysis data 
relating to cancer prognosis are logistic regression as 
a statistical method, and the artificial neural network 
tool MLFFBPNN (multilayer feed forward 
backpropagation neural network). The concept of 
fuzzy sets and fuzzy logic introduced by Zadeh 
(1965) has been applied in various disciplines, 
including medicine, and shown to provide a viable 
alternative to both artificial neural network based 
approach and statistical methods (Szczepaniak et al. 
2000). The FK-NN algorithm proposed by Keller et 
al. (1985) is a powerful pattern classifier.  
 
The FK-NN classifier has been successfully used for 
the prediction of nodal status and survival in series 
of breast cancer patients. The FK-NN based feature 
evaluation index is calculated using the class 
memberships, computed by means of the FK-NN 
algorithm and actual class memberships, which were 
previously known. Similar to pattern class 
memberships, this measurement gives a degree of 
importance between 0 and 1 for the subsets of the 
factors indicating how significant the subset is. The 
subset that yields the highest value of the index is 
considered as the most important one. The index can 
be used together with the predictive accuracy, as a 
secondary measurement, to precisely identify the 
most and the least important factor(s) and subset(s) 
of the factors (Seker et al. 2000a, b; 2002).  
FK-NN outcome of the predictive importance of 
molecular and cellular markers 
Previously we analysed the utility of cellular 
markers which included histology type, tumour 
grade, DNA ploidy, SPF, G0 G1/ G2M ratio, and 
pleomorphism indices employing logistic regression 
and MLFFBPNN techniques. The major focus in 
extending the inquiry was to analyse the outcome of 
the FK-NN technique and to compare its 
effectiveness with logistic regression and 
MLFFBPNN, the latter two techniques having been 
widely used for cancer prognosis.  
 
The FK-NN method yielded the highest predictive 
accuracy of 82-88% for both nodal involvement and 
survival analyses obtained from the two subsets of 
tumour grade, SPF, nuclear pleomorphism index and 
tumour histology type, DNA ploidy, SPF, G0 G1/ 
G2M ratio (Seker et al. 2002). An overview shows 
that the predictive accuracy for MLFFBPN in 
respect of both nodal involvement and survival is 
higher than the accuracy obtained with logistic 
regression analyses. But the performance of the FK-
NN is much superior to that of logistic regression and 
MLFFBPNN. Given this outcome, it would appear 
that the FK-NN technique may be deemed as a more 
reliable prognostic factor models (Seker et al. 2000 
a, b; 2002).  
 
Now returning to the question of the effects 
combining the biomarkers with ER/PR, we recently 
carried out FK-NN analyses of the expression status 
of the biomarker set comprising ER/PR, DNA 
Ploidy, and CCD and the clinical outcome. This has 
allowed a valuable insight into the effects of ER/PR. 
Unsurprisingly, the subset which included all the 
biomarkers seemed to be the best model that yielded 
the highest accuracy for predicting nodal status and 
patient survival (Seker and Sherbet, 2018 
unpublished work) (Table 4). But the previous study 
in which ER/PR had not been included found SPF to 
be the significant predictive factor (Seker et al. 
2002). Possibly, in the presence of ER/PR the 
predictive effect of SPF may have been diluted or 
diminished. Obviously ER/PR exerts substantial 
influences over the analytical outcome. This is 
possibly a result of the pro-proliferation effects that 
ER can exert, so counteracting the significance of 
SPF.  
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Table 4. Prediction of nodal status and survival by FK-NN analysis 
Prediction Model Parameter (K) Biomarker Set 
-Accuracy 
 -Sensitivity 
 -Specificity 
Standard Deviation for 
  -Accuracy 
  -Sensitivity 
  -Specificity 
Nodal 
Status 
1 [ER/PR; DNA Ploidy; CCD] 
0.6522 
 0.7155 
 0.5537 
0 
0.0054 
0.0084 
Survival 1 All the Biomarkers 
0.8040 
 0.8616 
 0.5967 
0.0016 
0.0021 
0.0151 
Note: In order to find the best FK-NN model, number of neighbourhoods (K) between 1 and 8 was assessed. In order to 
independently assess the predictive performance of all the models and make sure that the prediction is not biased towards 
particular sub-set of the samples selected, 2-fold cross validation was used, which is repeated x100 as different sub-sets of the 
data were randomly selected for each run. The mean and standard deviation are presented over 100 runs of the 2-fold cross 
validation in the following tables. The 2-fold cross validation means that 50% of the samples is used for training and the 
other half for testing. The results presented in the table above are the ones obtained for the test samples. (Seker and Sherbet, 
2018 unpublished data)
 
Recently, Pradhan et al. (2011) noted that tetraploid 
stage I and II showed greater recurrence than diploid 
ones, albeit not as high as aneuploid tumours with 
high DNA index. The diploid tumours showed far 
superior 5-year recurrence free survival. This 
confirms previous findings by Susini et al. (2007) 
that DNA aneuploidy was associated with higher 
risk of recurrence of endometrial cancer and also 
with reduced DFS. The patients with aneuploid 
tumours also carried a markedly lower 10-year 
survival risk than patients with diploid tumours. 
Whether p53, ER, and PR are important prognostic 
factors is still an open question. The ER/PR status 
might be associated with low grade and early stage 
endometrial carcinomas (Kounelis et al. 2000). 
However, some caution is probably warranted since 
differentiating between grades on ER/PR status is 
considered problematical and also the high grade 
tumours may be heterogeneous in many ways. Our 
overview of the current status of the affiliation and 
complementarity between ER/PR and the cellular 
markers is summarised in Table 5.  
  
Table 5. Comparison of ER/PR and DNA ploidy/SPF 
states in cancers 
Tumour type   ER/PR 
  Cellular marker 
  DNA ploidy/SPF/CCD 
Colorectal ? + (?) 
Prostate ? + 
Endometrial + (?) + 
Ovarian + + 
Breast + + 
Note: The + symbol in both columns denotes positive 
relationship between ER/PR and DNA ploidy/SPF. When 
the relationship is not unambiguous it is indicated by + (?) 
symbol. For colorectal and prostate cancers the 
relationship has not been explored. 
  
There are reasonable grounds which indicate that 
exposure to steroid hormones may reduce the risk of 
colorectal cancers in post-menopausal women 
(Johnson et al. 2009). Besides ER/PR other factors 
have been previously implicated in the perceived 
reduced colon cancer risk. Oestrogen therapy is a 
form of treatment for prostate cancer. But it may not 
be an ER/PR dependent outcome. Diethylstilbestrol 
reduces testosterone levels and in this way 
suppresses the growth of prostate cancer. 
Furthermore, the precise effect of ER/PR expression 
in prostate cancers is not satisfactorily resolved 
(Kowalska and Piastowska-Ciesielska, 2016).  
 
There is extensive evidence, both research and 
epidemiological, about the role of steroid hormones 
in the pathogenesis of these cancers. Overall, these 
thoughts are compatible with the sensitivity of breast 
and ovarian cancers to the therapeutic suppression of 
ER/PR. The linkup between the two parameters is 
unambiguous in breast and ovarian cancers and there 
are indications that it may subsist also in endometrial 
cancers. This review highlights that as far as breast 
cancers are concerned, the inclusion of the 
biomarkers DNA ploidy, SPF and CCD (G0 G1/ 
G2M) with ER/PR status would enhance the 
predictive utility of steroid receptor expression.  
 
Epilogue 
The ER/PR axis has a well-established role in cancer 
development and progression is widely used in 
assessing whether a cancer is benign or likely to be 
aggressive. The question posed here is whether 
cellular markers of ploidy, aneuploidy, SPF and cell 
cycle distribution, which also reflect the inherent 
genetic instability and the deregulated growth of 
cancers arising from the failure of cell cycle and 
immune checkpoints, can function in a 
complementary capacity with ER/PR. The wide 
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spectrum of evidence reviewed here does support the 
view that these markers accentuate the predictive 
power of ER/PR in respect of breast cancer 
progression. It also provides ample credibility to the 
view that they could assist in patient management.  
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